Ascelia Pharma AB (OSTO:ACE) Total Liabilities: kr13.95 Mil (As of Mar. 2026)


OSTO:ACE Ascelia Pharma AB OSTO:ACE
29 GF Score
Price kr2.93
! 1 Warning Sign
View Full Analysis

What is Ascelia Pharma AB Total Liabilities?

Ascelia Pharma AB OSTO:ACE -4.87% 29 Total Liabilities is kr13.95 Mil as of Mar. 2026. GuruFocus rates OSTO:ACE with a GF Score™ of 29/100. The stock has 1 warning sign investors should review.

Ascelia Pharma AB's Total Liabilities for the quarter that ended in Mar. 2026 was kr13.95 Mil.

Ascelia Pharma AB's quarterly Total Liabilities declined from Sep. 2025 (kr22.01 Mil) to Dec. 2025 (kr12.47 Mil) but then increased from Dec. 2025 (kr12.47 Mil) to Mar. 2026 (kr13.95 Mil).

Ascelia Pharma AB's annual Total Liabilities increased from Dec. 2023 (kr12.74 Mil) to Dec. 2024 (kr61.98 Mil) but then declined from Dec. 2024 (kr61.98 Mil) to Dec. 2025 (kr12.47 Mil).

Ascelia Pharma AB Total Liabilities Historical Data

* Premium members only.

The historical data trend for Ascelia Pharma AB's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ascelia Pharma AB Total Liabilities Chart

Ascelia Pharma AB Annual Data
Trend Jun17 Jun18 Jun19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Liabilities
Get a 7-Day Free Trial Premium Member Only 25.66 37.71 12.74 61.98 12.47

Ascelia Pharma AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 65.16 31.62 22.01 12.47 13.95
OSTO:ACE
29GF Score
Ascelia Pharma AB OSTO:ACE
Total Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Ascelia Pharma AB Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Ascelia Pharma AB's Total Liabilities for the fiscal year that ended in Dec. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=12.397+(0.072+-8.1878948066105E-16
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=12.47

Total Liabilities=Total Assets (A: Dec. 2025 )-Total Equity (A: Dec. 2025 )
=111.941-99.472
=12.47

Ascelia Pharma AB's Total Liabilities for the quarter that ended in Mar. 2026 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=13.946+(0+-0.00099999999999945
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=13.95

Total Liabilities=Total Assets (Q: Mar. 2026 )-Total Equity (Q: Mar. 2026 )
=96.866-82.921
=13.95

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of kr13.95 Mil mean?
Ascelia Pharma AB (OSTO:ACE) has a Total Liabilities of kr13.95 Mil as of Mar. 2026. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Ascelia Pharma AB and its competitors.
Is Ascelia Pharma AB's Total Liabilities too high?
Ascelia Pharma AB's current Total Liabilities is kr13.95 Mil. Overall, Ascelia Pharma AB has a GF Score™ of 29/100, reflecting its overall financial health beyond just this single metric.
How does Ascelia Pharma AB's Total Liabilities compare to VRTX and REGN?
Ascelia Pharma AB's Total Liabilities of kr13.95 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Biotechnology company?
A good Total Liabilities depends on the Biotechnology industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Ascelia Pharma AB and its competitors. Ascelia Pharma AB's current Total Liabilities is kr13.95 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ascelia Pharma AB stock overvalued right now?
Ascelia Pharma AB (OSTO:ACE) has a current Total Liabilities of kr13.95 Mil. The current Total Liabilities is kr13.95 Mil. Ascelia Pharma AB's overall GF Score™ is 29/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For Ascelia Pharma AB (OSTO:ACE), the current Total Liabilities is kr13.95 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Ascelia Pharma AB Business Description

Other Exchanges ACEs:UK
Address Hyllie Boulevard 34, Malmo, SWE, 215 32
Ascelia Pharma AB is a biotech company focused on orphan oncology treatments. The company develops and commercializes novel drugs that address unmet medical needs and have a clear development and market pathway. It has two drug candidates, Orviglance and Oncoral, in development. Orviglance (manganese chloride tetrahydrate) is an oral contrast agent for MR imaging developed to improve the detection and visualization of focal liver lesions (including liver metastases and primary tumors) in patients with impaired kidney function, and Oncoral is a novel oral irinotecan tablet in development.
29GF Score

Get the complete analysis for OSTO:ACE

Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr2.93
Price